Icon

EXPERT OPINION

Explore opinions from healthcare professionals who are passionate about optimising management of patients with type 2 diabetes.

VIRTUAL CONSULTATIONS - BEVERLEY BOSTOCK-COX

VIRTUAL CONSULTATIONS

BEVERLEY BOSTOCK-COX

Advanced Nurse Practitioner & Editor In Chief at Practice Nurse

The COVID-19 pandemic has resulted in the swift implementation of new models of care to minimise face-to-face contact between clinicians and patients. Below, Beverly Bostock-Cox provides tips and support on the methods of remote consulting available. The skills learnt and practised now will help establish how care can best be provided moving forward, making better use of NHS resources and offering different routes of access for patients. Please use the resources below to find out more.

icon

An Introduction to Remote Consultations

Watch video

icon

The Key Principles of Remote Consultations

Watch video

icon

Telephone Consultations

icon

Group Video Consultations

icon

Top 10 Tips

Download pdf

When are remote consultations appropriate and how effective are they? Links to evidence and resources relating to remote consulting are provided below.

THE RENAL IMPACT OF DIABETES – VIDEOS
Dr ANDREW FRANKEL

THE RENAL IMPACT OF DIABETES – VIDEOS
Dr ANDREW FRANKEL

Consultant Physician and Nephrologist, Imperial College Healthcare NHS Trust

icon

Why is it so important to ensure we are monitoring the renal function of people with diabetes?

Watch video

icon

Why is it so important for Renal and Diabetes Teams to work closely together and what do you feel a ‘gold standard’ diabetes/renal clinic would look like?

Watch video

icon

How does an SGLT2i work in the kidney to reduce HbA1c?

Watch video

icon

What is the risk of acute kidney injury with an SGLT2 inhibitor?

Watch video

icon

Why does renal function drop when you first initiate an SGLT2 inhibitor?

Watch video

IMPROVING DIABETES STEERING COMMITTEE – SGLT2 INHIBITORS: BENEFITS BEYOND HBA1C – TRANSLATING EVIDENCE INTO PRACTICE

IMPROVING DIABETES STEERING COMMITTEE – SGLT2 INHIBITORS: BENEFITS BEYOND HBA1C – TRANSLATING EVIDENCE INTO PRACTICE

Cardiovascular disease (CVD), including heart failure (HF), is a leading causes of morbidity and mortality in people with type 2 diabetes (T2D). This paper examines the role of SGLT2i therapy for people with T2D who are at risk of, or who have, CVD.

View the consensus document

Early Intensification of therapy for type 2 diabetes – Practice Nurse Supplement

Early Intensification of therapy for type 2 diabetes – Practice Nurse Supplement

The importance of achieving target HbA1c in the early years. Judy Downey, Practice Nurse 2018;48(01):12-16

Achieving good glycaemic control in the early years after diagnosis of type 2 diabetes reduces the time spent in a hyperglycaemic state and thus decreases the ‘glycaemic legacy’ effect – and so can be expected to lessen or delay the occurrence of complications.

View the Practice Nurse supplement

Managing type 2 diabetes, beyond glycaemic control – Practice Nurse Supplement

Managing type 2 diabetes, beyond glycaemic control – Practice Nurse Supplement

An extended role for newer agents in T2D Beverley Bostock-Cox, Practice Nurse 2018;48(10):25-29

Recent studies of newer glucose-lowering therapies indicate that some may also help to protect against cardiovascular and other complications of diabetes, beyond simply lowering blood glucose levels. In this article we will consider the increasing body of evidence for an extended role for some of the agent used in the management of type 2 diabetes.

View the Practice Nurse supplement

UK/CORP-19018(5)
Date of preparation: September 2020